Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DISOPHROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DISOPHROL.
CHILDREN'S ALLEGRA HIVES vs DISOPHROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination